These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 15331889

  • 21. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
    Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C.
    Nephrol Dial Transplant; 2006 Oct; 21(10):2846-50. PubMed ID: 16891642
    [Abstract] [Full Text] [Related]

  • 22. [Changing the frequency of administration of darbepoetin alfa (from weekly to fortnightly) maintains the haemoglobin levels in patients undergoing peritoneal dialysis].
    Bajo MA, Pérez Fontán M, Remón C, Sánchez-Tomero JA, Lladós F, Selgas R.
    Nefrologia; 2009 Oct; 29(2):136-42. PubMed ID: 19396319
    [Abstract] [Full Text] [Related]

  • 23. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
    Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC, Tezcan H, Waples J, Ward J, Yee LK.
    Cancer; 2004 Feb 15; 100(4):859-68. PubMed ID: 14770445
    [Abstract] [Full Text] [Related]

  • 24. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep 15; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 25. [Evaluation of efficacy of darbepoetin alfa administered once monthly as treatment of anemia in predialysis patients with chronic kidney disease].
    Martínez PM, García de Vinuesa S, Ortega Díaz M, Goicoechea M, Gómez Campderá F, Luño J.
    Nefrologia; 2005 Sep 15; 25(6):663-7. PubMed ID: 16514907
    [Abstract] [Full Text] [Related]

  • 26. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
    Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P, Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group.
    Circulation; 2008 Jan 29; 117(4):526-35. PubMed ID: 18195176
    [Abstract] [Full Text] [Related]

  • 27. Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents.
    Silver MR, Geronemus R, Krause M, Chen CY, Kewalramani R, Stehman-Breen C.
    Curr Med Res Opin; 2009 Jan 29; 25(1):123-31. PubMed ID: 19210145
    [Abstract] [Full Text] [Related]

  • 28. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J.
    Oncologist; 2007 Oct 29; 12(10):1253-63. PubMed ID: 17962619
    [Abstract] [Full Text] [Related]

  • 29. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study.
    Kessler M, Martínez-Castelao A, Siamopoulos KC, Villa G, Spinowitz B, Dougherty FC, Beyer U.
    Hemodial Int; 2010 Apr 29; 14(2):233-9. PubMed ID: 19888948
    [Abstract] [Full Text] [Related]

  • 30. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
    Fang YW, Chang CH.
    Perit Dial Int; 2009 Apr 29; 29(2):199-203. PubMed ID: 19293358
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
    Charu V, Belani CP, Gill AN, Bhatt M, Tomita D, Rossi G, Ben-Jacob A.
    Oncologist; 2007 Jun 29; 12(6):727-37. PubMed ID: 17602062
    [Abstract] [Full Text] [Related]

  • 32. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J.
    Nephrol Dial Transplant; 2003 Feb 29; 18(2):362-9. PubMed ID: 12543893
    [Abstract] [Full Text] [Related]

  • 33. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease.
    Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R.
    Clin Nephrol; 2005 May 29; 63(5):327-34. PubMed ID: 15909591
    [Abstract] [Full Text] [Related]

  • 34. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J.
    Best Pract Res Clin Haematol; 2005 May 29; 18(3):407-16. PubMed ID: 15792914
    [Abstract] [Full Text] [Related]

  • 35. Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
    Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA, Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators.
    N Engl J Med; 2010 Sep 16; 363(12):1146-55. PubMed ID: 20843249
    [Abstract] [Full Text] [Related]

  • 36. [Results of anemia treatment with darbepoetin alfa and erythropoietin beta in patients with chronic kidney disease].
    Wanic-Kossowska M.
    Pol Merkur Lekarski; 2010 Jan 16; 28(163):13-7. PubMed ID: 20369716
    [Abstract] [Full Text] [Related]

  • 37. Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease.
    Silver MR, Agarwal A, Krause M, Lei L, Stehman-Breen C.
    Am J Geriatr Pharmacother; 2008 Jun 16; 6(2):49-60. PubMed ID: 18675764
    [Abstract] [Full Text] [Related]

  • 38. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
    Mann J, Kessler M, Villa G, Martinez-Castelao A, Feldt-Rasmussen B, Cruz J, Hörl WH, Mattin C, Praml C, Wilkie M.
    Clin Nephrol; 2007 Mar 16; 67(3):140-8. PubMed ID: 17390738
    [Abstract] [Full Text] [Related]

  • 39. Effect of darbepoetin alfa on renal anemia in Japanese hemodialysis patients.
    Kusaba T, Ishida R, Nakayama M, Kato H, Uchiyama H, Sato K, Mori Y, Matsubara H, Kajita Y.
    Arzneimittelforschung; 2009 Mar 16; 59(9):435-9. PubMed ID: 19856789
    [Abstract] [Full Text] [Related]

  • 40. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
    Roger SD, Kolmakova E, Fung M, Malecki R, Vinhas J, Dellanna F, Thomas M, Manamley N, Ferenczi S.
    Nephrology (Carlton); 2014 May 16; 19(5):266-74. PubMed ID: 24506498
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.